Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aarhus University Hospital | OTHER |
| Max Planck Institute of Biochemistry | UNKNOWN |
| Deutsches Herzzentrum der Charité, Berlin | UNKNOWN |
Not provided
Not provided
Not provided
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:
Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Venous thromboembolism | Patients with acute deep vein thrombosis diagnosed on UL or pulmonary embolism diagnosed on CTA. >18 years of age. 120 patients in total. | ||
| Acute myocardial infarction | With ST segment elevation on ECG and confirmed culprit lesion on coronary angiography. >18 years of age. 50 patients in total. | ||
| Stroke | Stroke confirmed on MRI and diagnosis of atrial fibrillation. >18 years of age. 50 patients in total. | ||
| Healthy participants | No known or prior diseases, no medication. >18 years of age. 120 in total. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Platelet levels of heat shock protein 47 (HSP47) in patients with thrombosis compared to healthy controls | The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. | From enrollment to end of follow-up at 12 months after enrollment. At 3 time points. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in platelet levels of HSP47 over time in patients with thrombosis | The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. | From enrollment to 12 months of follow-up. Measured at 3 time points. |
| Platelet levels of HSP47 in association to platelet function |
Not provided
Inclusion Criteria:
VTE group:
AMI group:
Stroke group:
Healthy group:
- Healthy
Exclusion Criteria:
VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT
AMI
Stroke
- Stroke from other causes, e.g. findings pointing towards large vessel disease
Healthy
Not provided
Not provided
Not provided
Participants will be recruited at Aarhus University Hospital at the department of Cardiology (AMI, VTE), Neurology (Stroke) and Radiology (VTE) and at the Blood Bank (Healthy volunteers).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kathrine A Friis, MD, PhD-fellow | Contact | +45 20 65 27 32 | katfrs@rm.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University Hospital | Recruiting | Aarhus | Central Region | 8200 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37053338 | Background | Thienel M, Muller-Reif JB, Zhang Z, Ehreiser V, Huth J, Shchurovska K, Kilani B, Schweizer L, Geyer PE, Zwiebel M, Novotny J, Lusebrink E, Little G, Orban M, Nicolai L, El Nemr S, Titova A, Spannagl M, Kindberg J, Evans AL, Mach O, Vogel M, Tiedt S, Ormanns S, Kessler B, Dueck A, Friebe A, Jorgensen PG, Majzoub-Altweck M, Blutke A, Polzin A, Stark K, Kaab S, Maier D, Gibbins JM, Limper U, Frobert O, Mann M, Massberg S, Petzold T. Immobility-associated thromboprotection is conserved across mammalian species from bear to human. Science. 2023 Apr 14;380(6641):178-187. doi: 10.1126/science.abo5044. Epub 2023 Apr 13. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Platelet function will be assessed by platelet aggregation and activation using impedance aggregometry and flow cytometry. |
| From enrollment to 12 months of follow-up. Measured at 3 time points. |
| Platelet levels of HSP47 in association to fibrinolytic capacity | The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Fibrinolytic capacity will be assessed by ROTEM (R) tPA methods established in our lab, and by plasma fibrinolysis analyses. | From enrollment to 12 months of follow-up. Measured at 3 time points. |
| Deutsches Herzzentrum de Charité | Recruiting | Berlin | State of Berlin | 12203 | Germany |
|
| D002561 |
| Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |